DrAid™ for Liver Segmentation

by VinBrain Joint Stock Company  · Based in Vietnam → — AI-powered Liver Segmentation for Enhanced CT Scan Analysis
Gastroenterology Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

DrAid™ for Liver Segmentation is a web-based AI software designed to assist healthcare professionals in analyzing liver images obtained from CT scans. It provides semi-automated liver segmentation and offers tools for physicians to manually refine these segmentations and identify lesions. The software aids in evaluation and treatment planning by outputting critical measurements such as liver volume, lesion volume, and lesion dimensions. It operates on standard hospital/clinic workstations to support physicians and technicians in their workflow.

The technology processes multiphase CT DICOM images using an AI algorithm for semi-automated liver segmentation, complemented by manual editing capabilities. It includes a DICOM processing module, a liver segmentation viewer, measurement algorithms, and reporting tools.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Semi-automated liver segmentation using AI algorithm
  • Manual refinement of segmentations by physicians
  • Identification and segmentation of physician-identified lesions
  • Outputs liver volume, lesion volume, and lesion dimensions
  • Web-based software application for accessibility
  • Processes multiphase CT DICOM images
  • Includes DICOM processing module, liver segmentation viewer, measurement algorithms, and reporting tools
  • Assists in evaluation and treatment planning
  • Operates on standard hospital/clinic workstations
  • High accuracy: mean Dice score of 0.9649 and HD95 of 1.7061 for liver segmentation, with liver volume measurement error within 3%

Use Cases

  • Analyzing liver images from CT scans
  • Assisting in evaluation and treatment planning for liver conditions
  • Performing semi-automated liver segmentation
  • Identifying and measuring liver lesions
  • Supporting classification and localization of liver cancer lesions on CT images
  • Enhancing the screening and detection process for liver cancer

What Physicians Need to Know

Procedure Documentation
While DrAidu2122 for Liver Segmentation provides reporting tools for liver volume, lesion volume, and dimensions to aid evaluation and treatment planning, its primary function is not general endoscopy procedure documentation.
Quality Metrics Tracking
The tool's focus is on the accuracy of liver and lesion segmentation and volumetry from CT scans, not on tracking quality metrics specific to endoscopic procedures.
Physician Tip

For physicians utilizing DrAidu2122 for Liver Segmentation, focus on its strengths in pre-operative planning for liver resections, transplant evaluations, and oncology treatment assessments. The semi-automated segmentation and volumetry features can enhance consistency and efficiency in measuring liver and lesion volumes, aiding in precise surgical strategies and monitoring disease progression. Always review and manually refine segmentations as needed, as the AI acts as an assistant, not a definitive diagnostic tool. Leverage its capabilities for detecting and characterizing liver lesions, including hepatocellular carcinoma (HCC), from multiphase CT images.

DrAidu2122 for Liver Segmentation is a web-based software application designed to process multiphase CT DICOM images. It can be easily integrated and deployed into existing hospital systems such as PACS (Picture Archiving and Communication System), HIS (Hospital Information System), RIS (Radiology Information System), and EMR (Electronic Medical Record). VinBrain offers options for both cloud and on-premises deployment through the DrAid Appliance, ensuring flexibility and adherence to data privacy and security standards like HIPAA and NIST.

Details

Category Gastroenterology AI, Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentWeb-based software with options for cloud or on-premises availability via DrAid™ Appliance.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

DrAid™ for Liver Segmentation received FDA 510(k) clearance (K241543) on December 5, 2024, as a web-based software for visualization, evaluation, and reporting of liver and physician-identified lesions using multiphase CT images for patients aged 22 and older.
Integrations
EHR Not specified
Specialties Gastroenterology, Oncology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DrAid™ for Liver Segmentation

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FDA
DrAidu2122 for Liver Segmentation (K241543) u2014 FDA 510(k) evidence
This FDA 510(k) premarket notification indicates that DrAidu2122 for Liver Segmentation, developed by VinBrain Joint Stock Company, was cleared on December 6, 2024, under product code QIH for Radiology. The device is a web-based AI software designed to assist healthcare professionals in analyzing liver images from CT scans.
2024-12
X-ray Interpreter
DrAidu2122 for Liver Segmentation | FDA Radiology AI Device - X-ray Interpreter
This article details the FDA clearance of DrAidu2122 for Liver Segmentation on December 6, 2024, highlighting its function as a web-based AI software for semi-automated liver segmentation and lesion identification from CT scans. It emphasizes the software's role in aiding evaluation and treatment planning without providing direct diagnoses.
2024-12
FDA
VinBrain Joint Stock Company - accessdata.fda.gov
This FDA document confirms the substantial equivalence of DrAidu2122 for Liver Segmentation to predicate devices, noting its web-based, non-invasive image analysis application for liver and physician-identified lesion visualization, evaluation, and reporting using CT scans. It also outlines the software's semi-automated quantitative imaging function utilizing an AI algorithm.
2024-12
FDA
K241543 - 510(k) Premarket Notification - FDA
This FDA premarket notification provides details about VinBrain Joint Stock Company as the applicant for DrAidu2122 for Liver Segmentation, identified by the 510(k) number K241543. It lists the applicant and correspondent contact information and links to relevant regulatory information.
2026-06
Innolitics
DrAidu2122 for Liver Segmentation (K241543) u2014 FDA 510(k) - Innolitics
Innolitics provides an overview of DrAidu2122 for Liver Segmentation's FDA 510(k) clearance (K241543) on December 6, 2024, categorizing it as a Class 2 medical device. The platform describes the software's functionality in processing multiphase DICOM CT images for liver and lesion analysis, utilizing an AI algorithm for semi-automated segmentation.
2024-12
FDA
TPLC - Total Product Life Cycle - accessdata.fda.gov
This FDA Total Product Life Cycle (TPLC) entry confirms the substantial equivalence of DrAidu2122 for Liver Segmentation (K241543) from VinBrain Joint Stock Company.
2026-06
Innolitics
QIH u00b7 Automated Radiological Image Processing Software u2014 FDA Product Code | Innolitics
This Innolitics page, detailing FDA product code QIH for Automated Radiological Image Processing Software, lists DrAidu2122 for Liver Segmentation (K241543) as a recently cleared device on December 6, 2024. It describes the scope of such software, including AI implementations for image processing and analysis.
2024-12

Videos

Product demos, reviews, and walkthroughs for DrAid™ for Liver Segmentation.

Loading videos...

View all on YouTube

Frequently Asked Questions

Yes, DrAidu2122 for Liver Segmentation received FDA 510(k) clearance (K241543) on December 6, 2024, indicating it has met the rigorous safety and efficacy standards for clinical use in the United States. This approval allows it to assist healthcare professionals in analyzing liver images from CT scans.
DrAidu2122 for Liver Segmentation is a web-based software designed to process multiphase CT DICOM images and operates on standard hospital/clinic workstations. It utilizes DICOM for image processing and reporting, allowing for automated image transfer and return of segmented results into your viewing environment.
While DrAidu2122 demonstrates high accuracy (mean Dice score of 0.9649 in validation), it is a semi-automated tool with manual editing capabilities, implying physician review is crucial. Like all AI, its performance might be challenged by highly atypical anatomies, severe motion artifacts, or rare pathologies not extensively represented in its training data.
DrAidu2122 for Liver Segmentation has demonstrated high accuracy, with liver volume measurement error within 3% in validation studies. AI-powered segmentation generally offers significant efficiency gains, reducing processing time from minutes (manual) to seconds, while maintaining or exceeding accuracy compared to manual methods.
Specific pricing models for DrAidu2122 for Liver Segmentation are not publicly detailed in the provided search results. However, AI solutions often utilize per-case fees, subscription models, or site licenses, and while DrAidu2122 is web-based, integration with existing IT infrastructure may involve setup costs.
AI-powered segmentation can provide results significantly faster than manual methods, often within seconds to minutes. Physicians retain ultimate medico-legal responsibility for patient care, meaning AI outputs should always be critically reviewed and validated before being used for diagnosis or treatment planning.
While specific details for DrAidu2122 for Liver Segmentation were not found, AI healthcare solutions generally implement robust security frameworks, including data encryption, access controls, and anonymization protocols to comply with regulations like HIPAA and GDPR. FDA approval processes also involve rigorous evaluations of quality and safety standards.

Related Tools

GI Genius Module
Cosmo Artificial Intelligence - Ai, Ltd.
Gastroenterology AI
The GI Genius™ intelligent endoscopy module is an AI-powered system designed to assist physicians in the real-time detection of colorectal polyps during colonoscopy, acting as a "second set of eyes" to enhance visualization and improve detection rates.
Cologuard / Cologuard Plus
Exact Sciences
Gastroenterology AI
Cologuard and Cologuard Plus are FDA-approved, non-invasive stool DNA colorectal cancer screening tests from Exact Sciences for average-risk individuals aged 45 and older. Cologuard Plus offers enhanced accuracy and fewer false positives. These at-home tests detect DNA markers and blood in stool to identify early-stage colorectal cancer.
Most insured patients pay $0
Deep Capsule
Digestaid - Artificial Intelligence Development SA
Gastroenterology AI
Deep Capsule is an AI software tool that assists in reviewing capsule endoscopy images by detecting and differentiating lesions, stratifying hemorrhagic potential, and highlighting clinically relevant frames for physician validation.
Pure-Vu
Motus GI
Gastroenterology AI
The Pure-Vu System is an FDA-approved device that facilitates intra-procedural cleansing of the GI tract to improve visualization during colonoscopies and gastroscopies, especially in cases of inadequate bowel preparation or GI bleeding.
Paid
aScope Gastro
Ambu
Gastroenterology AI
The Ambu aScope Gastro is a sterile, single-use gastroscope with advanced imaging and design features for a variety of endoscopic procedures in the upper GI tract, offering portability and eliminating reprocessing.
Contact for pricing
CADDIE™ Computer-Aided Detection (CADe) Device
Odin Medical Ltd. (an Olympus Corporation company)
Clinical Decision Support & Reference
CADDIE™ is the first cloud-based AI technology to receive FDA clearance, designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures. This AI tool, developed by Odin Medical Ltd., an Olympus Corporation company, supports real-time polyp detection and characterization, improves adenoma detection rates, and integrates seamlessly into existing clinical workflows.
Per procedure cost effectiveness

See all Gastroenterology AI tools →

More from VinBrain Joint Stock Company

DrAid for Radiology v1
VinBrain Joint Stock Company
Radiology & Imaging AI
DrAid for Radiology v1 is an FDA-cleared AI assistant by VinBrain, designed to enhance diagnostic imaging for radiologists. It uses AI to interpret chest X-rays, identify abnormalities like pneumothorax, and prioritize cases, improving accuracy and workflow efficiency.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-21 | First Added: 2026-04-21
AI Tool Finder
AI-powered search. Results may not be comprehensive.